An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia

Gertjan J L Kaspers, Denise Niewerth, Bram A J Wilhelm, Peggy Scholte-van Houtem, Marta Lopez-Yurda, Johannes Berkhof, Jacqueline Cloos, Valerie de Haas, Ron A Mathôt, Andishe Attarbaschi, André Baruchel, Eveline S de Bont, Franca Fagioli, Claudia Rössig, Thomas Klingebiel, Barbara De Moerloose, Brigitte Nelken, Giuseppe Palumbo, Dirk Reinhardt, Pierre-Simon RohrlichPauline Simon, Arend von Stackelberg, Christian Michel Zwaan

Research output: Contribution to journalArticle

Abstract

This trial explored the efficacy of re-induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia. Patients were randomized 1:1 to bortezomib (1.3 mg/m2 /dose) administered early or late to a dexamethasone and vincristine backbone. Both groups did not differ regarding peripheral blast count on day 8, the primary endpoint. After cycle 1, 8 of 25 (32%) patients achieved complete remission with incomplete blood count recovery, 7 (28%) a partial remission and 10 had treatment failure. Most common grade 3-4 toxicities were febrile neutropenia (31%) and pain (17%). Bortezomib was safely combined with vincristine. Bortezomib rarely penetrated the cerebrospinal fluid.

Original languageEnglish
Pages (from-to)523-527
Number of pages5
JournalBritish Journal of Haematology
Volume181
Issue number4
DOIs
Publication statusPublished - May 2018

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
Vincristine
Febrile Neutropenia
Induction Chemotherapy
Treatment Failure
Dexamethasone
Cerebrospinal Fluid
Pain
Bortezomib

Cite this

Kaspers, G. J. L., Niewerth, D., Wilhelm, B. A. J., Scholte-van Houtem, P., Lopez-Yurda, M., Berkhof, J., ... Zwaan, C. M. (2018). An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia. British Journal of Haematology, 181(4), 523-527. https://doi.org/10.1111/bjh.15233

An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia. / Kaspers, Gertjan J L; Niewerth, Denise; Wilhelm, Bram A J; Scholte-van Houtem, Peggy; Lopez-Yurda, Marta; Berkhof, Johannes; Cloos, Jacqueline; de Haas, Valerie; Mathôt, Ron A; Attarbaschi, Andishe; Baruchel, André; de Bont, Eveline S; Fagioli, Franca; Rössig, Claudia; Klingebiel, Thomas; De Moerloose, Barbara; Nelken, Brigitte; Palumbo, Giuseppe; Reinhardt, Dirk; Rohrlich, Pierre-Simon; Simon, Pauline; von Stackelberg, Arend; Zwaan, Christian Michel.

In: British Journal of Haematology, Vol. 181, No. 4, 05.2018, p. 523-527.

Research output: Contribution to journalArticle

Kaspers, GJL, Niewerth, D, Wilhelm, BAJ, Scholte-van Houtem, P, Lopez-Yurda, M, Berkhof, J, Cloos, J, de Haas, V, Mathôt, RA, Attarbaschi, A, Baruchel, A, de Bont, ES, Fagioli, F, Rössig, C, Klingebiel, T, De Moerloose, B, Nelken, B, Palumbo, G, Reinhardt, D, Rohrlich, P-S, Simon, P, von Stackelberg, A & Zwaan, CM 2018, 'An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia', British Journal of Haematology, vol. 181, no. 4, pp. 523-527. https://doi.org/10.1111/bjh.15233
Kaspers, Gertjan J L ; Niewerth, Denise ; Wilhelm, Bram A J ; Scholte-van Houtem, Peggy ; Lopez-Yurda, Marta ; Berkhof, Johannes ; Cloos, Jacqueline ; de Haas, Valerie ; Mathôt, Ron A ; Attarbaschi, Andishe ; Baruchel, André ; de Bont, Eveline S ; Fagioli, Franca ; Rössig, Claudia ; Klingebiel, Thomas ; De Moerloose, Barbara ; Nelken, Brigitte ; Palumbo, Giuseppe ; Reinhardt, Dirk ; Rohrlich, Pierre-Simon ; Simon, Pauline ; von Stackelberg, Arend ; Zwaan, Christian Michel. / An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia. In: British Journal of Haematology. 2018 ; Vol. 181, No. 4. pp. 523-527.
@article{2aaa3ee9bdb546aa83b48a2f476e2de8,
title = "An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia",
abstract = "This trial explored the efficacy of re-induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia. Patients were randomized 1:1 to bortezomib (1.3 mg/m2 /dose) administered early or late to a dexamethasone and vincristine backbone. Both groups did not differ regarding peripheral blast count on day 8, the primary endpoint. After cycle 1, 8 of 25 (32{\%}) patients achieved complete remission with incomplete blood count recovery, 7 (28{\%}) a partial remission and 10 had treatment failure. Most common grade 3-4 toxicities were febrile neutropenia (31{\%}) and pain (17{\%}). Bortezomib was safely combined with vincristine. Bortezomib rarely penetrated the cerebrospinal fluid.",
author = "Kaspers, {Gertjan J L} and Denise Niewerth and Wilhelm, {Bram A J} and {Scholte-van Houtem}, Peggy and Marta Lopez-Yurda and Johannes Berkhof and Jacqueline Cloos and {de Haas}, Valerie and Math{\^o}t, {Ron A} and Andishe Attarbaschi and Andr{\'e} Baruchel and {de Bont}, {Eveline S} and Franca Fagioli and Claudia R{\"o}ssig and Thomas Klingebiel and {De Moerloose}, Barbara and Brigitte Nelken and Giuseppe Palumbo and Dirk Reinhardt and Pierre-Simon Rohrlich and Pauline Simon and {von Stackelberg}, Arend and Zwaan, {Christian Michel}",
note = "{\circledC} 2018 John Wiley & Sons Ltd.",
year = "2018",
month = "5",
doi = "10.1111/bjh.15233",
language = "English",
volume = "181",
pages = "523--527",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "4",

}

TY - JOUR

T1 - An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia

AU - Kaspers, Gertjan J L

AU - Niewerth, Denise

AU - Wilhelm, Bram A J

AU - Scholte-van Houtem, Peggy

AU - Lopez-Yurda, Marta

AU - Berkhof, Johannes

AU - Cloos, Jacqueline

AU - de Haas, Valerie

AU - Mathôt, Ron A

AU - Attarbaschi, Andishe

AU - Baruchel, André

AU - de Bont, Eveline S

AU - Fagioli, Franca

AU - Rössig, Claudia

AU - Klingebiel, Thomas

AU - De Moerloose, Barbara

AU - Nelken, Brigitte

AU - Palumbo, Giuseppe

AU - Reinhardt, Dirk

AU - Rohrlich, Pierre-Simon

AU - Simon, Pauline

AU - von Stackelberg, Arend

AU - Zwaan, Christian Michel

N1 - © 2018 John Wiley & Sons Ltd.

PY - 2018/5

Y1 - 2018/5

N2 - This trial explored the efficacy of re-induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia. Patients were randomized 1:1 to bortezomib (1.3 mg/m2 /dose) administered early or late to a dexamethasone and vincristine backbone. Both groups did not differ regarding peripheral blast count on day 8, the primary endpoint. After cycle 1, 8 of 25 (32%) patients achieved complete remission with incomplete blood count recovery, 7 (28%) a partial remission and 10 had treatment failure. Most common grade 3-4 toxicities were febrile neutropenia (31%) and pain (17%). Bortezomib was safely combined with vincristine. Bortezomib rarely penetrated the cerebrospinal fluid.

AB - This trial explored the efficacy of re-induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia. Patients were randomized 1:1 to bortezomib (1.3 mg/m2 /dose) administered early or late to a dexamethasone and vincristine backbone. Both groups did not differ regarding peripheral blast count on day 8, the primary endpoint. After cycle 1, 8 of 25 (32%) patients achieved complete remission with incomplete blood count recovery, 7 (28%) a partial remission and 10 had treatment failure. Most common grade 3-4 toxicities were febrile neutropenia (31%) and pain (17%). Bortezomib was safely combined with vincristine. Bortezomib rarely penetrated the cerebrospinal fluid.

U2 - 10.1111/bjh.15233

DO - 10.1111/bjh.15233

M3 - Article

C2 - 29676440

VL - 181

SP - 523

EP - 527

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -